SITE013-0183

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE013 (USA) · Dr. Clarke
consented 2022-10-07

AEs

Serious

Dropout signal

–

Adverse events

severe serious assessed

Grade 4 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-10-25 (study day 9); relationship: N; serious criteria: life-threatening

mild assessed

Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-11-08 (study day 23); relationship: not assessed

mild assessed

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-11-16 (study day 31); relationship: not assessed

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-12-09 (study day 54); relationship: not assessed

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-12-17 (study day 62); relationship: not assessed

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-12-23 (study day 68); relationship: not assessed

mild assessed

Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-12-27 (study day 72); relationship: N

Data queries

No data queries.